Fig. 2

Azacytidine mitigates skin fibrosis on day +52. Balb/cJ mice were injected i.v. with 10.10⁶ bone marrow cells and 70.10⁶ splenocytes from B10.D2 donor mice after lethal irradiation. Mice were then given (or not) azacytidine (AZA, 2 mg/kg) administered subcutaneously every 48 h from day +10 to day +30. At sacrifice (day +52), histology was performed on lung and skin samples to evaluate fibrosis (Goldner’s Trichrome) and monocyte infiltration (CD11b staining). a, b Quantification (a) and representative images (b) (Trichrome 150×) of skin fibrosis in control (n = 5) and AZA-treated (n = 7) mice. Ratios were calculated by dividing total thickness (TT, from epidermis to sub-cutaneous muscle layer) by collagen thickness (CT, stained by Goldner’s Trichrome). c, d Ashcroft [36] quantification (c) and representative images (d) (Trichrome 100×) of lung fibrosis in control (n = 4) and AZA-treated (n = 7) mice. e, f Quantification (e) and representative images (f) (IHC 100×) of monocyte infiltration in the skin of control (n = 5) and AZA-treated (n = 8) mice. Results are expressed as median, 25th and 75th percentiles of the distribution (boxes), and whiskers extending to the 5th and 95th percentiles. *P < 0.05